S&P: Boston Scientific unchanged

Standard & Poor's said that the U.S. Supreme Court's rejection of an appeal by Boston Scientific Corp. (BB+/negative) regarding last week's $703 million jury finding will have no impact on the rating.

Boston Scientific continues to explore other avenues of appeal and in the event that it was unsuccessful, the company had $1.6 billion of cash as of June 30, the agency noted.

In addition, since amended covenants permit a $500 million carve-out for legal judgments, the agency said that the company's ability to comply with covenants will not be compromised.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.